Notably, CLL patients exhibiting mutations in BTK and/or PLCγ2, a phenotype that is more prevalent among individuals unresponsive to BTKi therapy, are three times more likely to possess TP53 aberrations than their counterparts devoid of such mutations [35]. The gene discussed is PLCG2; the disease is B-cell chronic lymphocytic leukemia.